Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;92(12):3839-3842.
doi: 10.1002/jmv.25836. Epub 2020 Apr 15.

Relevance of reviewing endpoint analysis for negative results on the Xpert Xpress Flu/RSV

Nancy Matic  1   2 , Gordon Ritchie  1   2 , Tanya Lawson  1 , Loretta Karakas  1 , Marc G Romney  1   2 , Christopher F Lowe  1   2
Affiliations

Relevance of reviewing endpoint analysis for negative results on the Xpert Xpress Flu/RSV

Nancy Matic et al. J Med Virol. 2020 Dec.

Abstract

After the implementation of the Xpert Xpress Flu/respiratory syncytial virus (RSV) assay for rapid respiratory molecular testing, we investigated the significance of reported endpoint values for influenza A, influenza B, and RSV). This study prospectively analyzed nasopharyngeal swabs submitted to our virology laboratory in the 2018/19 influenza season. Initial testing was performed on the Xpress Flu/RSV assay. Samples were further tested on a laboratory-developed multiplex polymerase chain reaction (laboratory-developed multiplex respiratory test [LDT]) if the sample was reported as negative by the Xpress Flu/RSV but had an elevated endpoint value ≥5 for any respiratory virus target. There were 1040 negative results on the Xpress Flu/RSV; thirty-one had at least one endpoint value ≥5 [influenza A (25), influenza B (1), RSV (2), influenza A/RSV (1), and influenza A/B/RSV (2)]. Five samples (5/31, 16.1%) were positive on the LDT for influenza A or RSV. In contrast, the positivity rate on the LDT for negative Xpress Flu/RSV samples with endpoint values less than 5 was 0.35% (P < .0001). A threshold for endpoint values could not reliably be established to differentiate a potential influenza A positive result from a negative result on the LDT. Routine evaluation ofendpoint values should be a consideration for laboratories implementing Xpress Flu/RSV, in addition to supplementary respiratory virus testing for clinically relevant situations.

Keywords: Xpert; endpoint; influenza A; quality control; rapid PCR.

PubMed Disclaimer

References

REFERENCES

    1. Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017;5(5):401-411.
    1. Lowe CF, Leung V, Karakas L, et al. Targeted management of influenza A/B outbreaks incorporating the cobas® Influenza A/B & RSV into the virology laboratory. J Hosp Infect. 2018;101(1):38-41.
    1. Cepheid. Xpert® Xpress Flu/RSV product insert. 2018.
    1. Lowe CF, Payne M, Puddicombe D, et al. Antimicrobial stewardship for hospitalized patients with viral respiratory tract infections. Am J Infect Control. 2017;45(8):872-875.
    1. Petrie JG, Ohmit SE, Cowling BJ, et al. Influenza transmission in a cohort of households with children: 2010-2011. PLoS One. 2013;8(9):2010-2011.

MeSH terms

LinkOut - more resources